Abstract:Key PointsTumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a molecule belonging to the tumour necrosis factor (TNF) superfamily. In humans, two TRAIL receptors (TRAIL-R1 and TRAIL-R2) and in mice one receptor (mTRAIL-R) can signal apoptosis upon binding of TRAIL.Induction of apoptosis is enabled through recruitment of the death-inducing signalling complex (DISC). This complex leads to activation of a caspase cascade.TRAIL–TRAIL-R binding can also induce non-apoptotic signalling including via activation of nuclear factor-κB (NF-κB), p38, ERK, SRC and RAC1.Mice deficient in TRAIL or mTRAIL-R are more susceptible to various cancers whereas conditional deletion of mTRAIL-R in Kras- driven cancers ameliorates disease progression. TRAIL–TRAIL-R blockade might therefore be a therapeutic option for patients with KRAS-mutated cancers.TRAIL–TRAIL-R interaction on myeloid-derived suppressor cells in the tumour microenvironment can limit their lifespan and thereby tip the balance towards an antitumour immune environment. Hence, patients with an immunosuppressive cancer microenvironment might benefit from TRAIL-R agonistic therapy.Clinical trials testing an untagged form of recombinant TRAIL, agonistic TRAIL-R1 or TRAIL-R2-specific antibodies or antibody derivatives with higher crosslinking capacity have not led to anticipated therapeutic benefit.Preclinical approaches using therapeutic combinations comprising optimized TRAIL-R agonists and recently discovered powerful apoptosis sensitizers are, however, promising. Therefore, such novel pro-apoptotic combination therapies should be tested in clinical trials.Several drugs, some of which have been approved by the US Food and Drug Administration, induce extrinsic apoptosis through autocrine engagement of the TRAIL–TRAIL-R pathway. Therefore, expression of TRAIL apoptosis pathway components, as well as lack of expression of inhibitors thereof, might be useful for patient selection in clinical trials testing the efficacy of such drugs.

Relationship Between Tumor Tolerance to TRAIL and Its Receptors

TRAIL and Cancer Therapy

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Cell To Cell Contact Required For Bystander Effect Of The Tnf-Related Apoptosis-Inducing Ligand (Trail) Gene

Membrane-bound Ligand-Dependent Bystander Effect of the TNF-related Apoptosis-Inducing Ligand (TRAIL)

Developing TRAIL/TRAIL death receptor-based cancer therapies

Mechanism of TRAIL Induced Tumor Cell Apoptosis and Application of TRAIL Based on Tumor Therapy

Inducible Resistance Of Tumor Cells To Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2-Mediated Apoptosis By Generation Of A Blockade At The Death Domain Function

Molecular Mechanisms of TRAIL-induced Apoptosis of Cancer Cells

The Investigation of the Relationship Between Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Tumor Therapy

TNF-related Apoptosis-Inducing Ligand and Tumor

[Action of Apoptosis-Induced Ligand Gene in Relation to Tumor Necrosis Factor on Human Colon Cancer Cell Line HT29].

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies

TRAIL Agonists on Clinical Trials for Cancer Therapy: the Promises and the Challenges.

Tumor-Derived Mutations in the Trail Receptor Dr5 Inhibit Trail Signaling Through the Dr4 Receptor by Competing for Ligand Binding

Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges

Redistribution of DR4 and DR5 in Lipid Rafts Accounts for the Sensitivity to TRAIL in NSCLC Cells

Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways

Getting TRAIL back on track for cancer therapy